Saturday 17 October 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.
5.53
0.21
−3.66%
Follow SLDB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
— | — | — | — | — | 1.83 | (2.87) | — | — | — |
P/S ratio |
— | — | — | — | — | 13.72 | 4.25 | — | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 5.89 | (0.25) | — | — | — |
P/Operating CF |
— | — | — | — | — | (8.95) | (1.39) | — | — | — |
P/B ratio |
— | — | — | — | — | 0.90 | 0.23 | — | — | — |
Price to Tangible BV |
— | — | — | — | — | 0.90 | 0.23 | — | — | — |
EV/Sales |
— | — | — | — | — | (1.52) | (14.60) | — | — | — |
EV/EBITDA |
— | — | — | — | — | 0.30 | 1.58 | — | — | — |
EV/Operating CF |
— | — | — | — | — | 0.27 | 1.68 | — | — | — |
EV/FCF |
— | — | — | — | — | 0.26 | 1.64 | — | — | — |
Quick Ratio |
5.48 | 6.14 | 9.81 | 4.57 | 6.32 | 8.81 | 9.50 | 8.52 | 4.92 | 5.65 |
Current Ratio |
5.82 | 6.27 | 10.31 | 4.72 | 6.49 | 9.43 | 9.76 | 8.94 | 5.20 | 6.14 |
Net Debt/EBITDA |
1.51 | 1.28 | 1.64 | 0.71 | 1.83 | 3.04 | 2.04 | 1.18 | 1.14 | 1.05 |
Debt/Assets |
0.00% | 0.00% | 0.62% | 0.71% | 0.31% | 0.13% | 0.65% | 0.75% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.17 | 1.10 | 0.94 | 0.79 | 0.64 | 1.08 | 1.14 | 0.98 | 0.80 | 0.90 |
Capex/Depreciation |
(0.70) | (3.48) | (5.27) | (1.72) | (0.23) | (0.31) | (0.91) | (8.76) | 0.57 | 4.49 |
Interest Coverage |
(69.31) | (250.49) | (122.27) | (75.52) | (768.75) | (1,128.97) | (40.69) | (236.94) | (381.55) | 882.79 |
| 59.61% | 80.95% | (226.92%) | (114.24%) | (83.24%) | (42.43%) | (40.96%) | (56.79%) | (94.57%) | (109.90%) | |
| (35.77%) | (67.31%) | (69.32%) | (96.45%) | (64.30%) | (35.78%) | (34.91%) | (45.16%) | (70.53%) | (82.78%) | |
ROIC |
0.00% | 0.00% | (1,322.09%) | 0.00% | 0.00% | (6,228.79%) | 0.00% | (1,598.96%) | 0.00% | 0.00% |
Return on Tangible Assets |
(51.35%) | (63.60%) | (59.09%) | (147.13%) | (61.93%) | (35.13%) | (41.58%) | (78.80%) | (94.62%) | (98.96%) |
Average Days of Receivables |
— | — | — | — | — | 2.95 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 431.27% | 968.87% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 199.23% | 357.65% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 98.19% | 93.12% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | 1.06 | 3.58 | — | — | — |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Earnings Yield |
— | — | — | — | — | (39.41%) | (177.70%) | — | — | — |
Free Cash Flow Yield |
— | — | — | — | — | (42.30%) | (209.86%) | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.91 | 0.95 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(177.58) | (47.48) | (31.64) | (34.50) | (16.35) | (10.92) | (11.51) | (4.74) | (2.45) | (1.79) |
Capex per Share |
(3.46) | (2.50) | (3.50) | (1.63) | (0.26) | (0.18) | (0.28) | (0.08) | (0.02) | (0.01) |
Free Cash Flow per Share |
(181.04) | (49.98) | (35.15) | (36.13) | (16.61) | (11.10) | (11.79) | (4.81) | (2.47) | (1.80) |
Cash per Share |
332.37 | 75.97 | 55.20 | 31.08 | 44.70 | 29.19 | 25.11 | 6.22 | 3.65 | 2.16 |
Shareholders Equity per Share |
(334.39) | (65.09) | 56.42 | 29.79 | 38.15 | 29.25 | 24.87 | 6.36 | 3.36 | 2.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(334.39) | (65.09) | 56.42 | 29.79 | 38.15 | 29.25 | 24.87 | 6.36 | 3.36 | 2.06 |
Free Cash Flow |
(20.51) | (45.50) | (77.97) | (97.10) | (57.50) | (79.04) | (100.39) | (95.69) | (100.66) | (157.36) |
Working Capital |
33.10 | 59.39 | 116.16 | 68.03 | 134.42 | 199.01 | 197.13 | 115.22 | 127.05 | 171.98 |
Capital Expenditures |
(0.39) | (2.28) | (7.78) | (4.39) | (0.90) | (1.28) | (2.41) | (1.51) | (0.65) | (1.07) |
Net Current Asset Value |
(38.55) | (64.79) | 114.23 | 62.88 | 119.82 | 198.44 | 171.05 | 91.28 | 105.89 | 152.93 |
EV/EBIT |
— | — | — | — | — | 0.29 | 1.54 | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.30 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.24 | 0.27 | 0.14 | 0.22 | 0.48 | 0.63 | 0.27 | 0.03 | (0.24) | (0.06) |
Cash ROIC |
8,996.49% | (459.50%) | (31.38%) | (59.10%) | (20.01%) | (18.99%) | (23.51%) | (38.07%) | (35.18%) | (42.63%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Payables |
1.80 | 4.03 | 4.38 | 5.41 | 5.20 | 3.87 | 3.85 | 2.64 | 3.13 | 3.73 |
Average Assets |
48.17 | 58.41 | 107.90 | 121.53 | 137.32 | 201.77 | 246.32 | 212.60 | 176.80 | 210.60 |
Average Common Equity |
(28.91) | (48.57) | 32.96 | 102.62 | 106.07 | 170.15 | 209.94 | 169.07 | 131.86 | 158.63 |
Columns are period end dates